Creo Medical Group PLC Total Voting Rights (1152X)
April 30 2021 - 01:00AM
UK Regulatory
TIDMCREO
RNS Number : 1152X
Creo Medical Group PLC
30 April 2021
Creo Medical Group plc
("Creo" or the "Company")
Total Voting Rights
The Company's total issued share capital consists of 157,940,390
Ordinary Shares of 0.1 pence each ("Ordinary Shares") with one
voting right per Ordinary Share. The Company does not hold any
Ordinary Shares in Treasury.
Therefore, the total number of voting rights in the Company is
157,940,390. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change of their
interest in, the Company under the FCA's Disclosure and
Transparency Rules.
Ends
Enquires:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7584
391 303
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical Advanced Energy Platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA Advanced Energy
Platform powered by its unique full spectrum Kamaptive Technology
to market, enabling a suite of medical devices which the Company
has designed, initially for the emerging field of GI therapeutic
endoscopy, an area with high unmet needs. The CROMA Advanced Energy
platform will be developed further for bronchoscopy and laparoscopy
procedures. The Company believes its technology can impact the
landscape of surgery and endoscopy by providing a safer,
less-invasive and more cost-efficient option of treatment. An
overview of the Creo Medical device technology portfolio can be
seen here:
https://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf
For more information about Creo Medical please see our website,
www.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRZZGZDFLRGMZM
(END) Dow Jones Newswires
April 30, 2021 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Mar 2023 to Mar 2024